IBD in Different Age Groups

March 27 – 28, 2009
Hotel Meliá Castilla
Capitán Haya, 43
28020 Madrid
Spain

Program
12 credit hours (CME) have been awarded for the Falk Symposium 168 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG).
Preface

Dear colleagues,

On behalf of the Scientific Committee I would like to welcome you to the Falk Symposium 168 “IBD in different age groups” to be held in Madrid.

This approach is justified by the fact that the incidence in early life is raising, with all problems inherent to physical and mental development, and leads to a sharp growth of the number of patients suffering of an already long standing chronic disease in young ages and early adulthood. As a consequence, the number of elder patients is also increasing. We face then a situation where risk factors and response to therapy may be different as the life of these patients goes by.

We think that for the first time an IBD symposium takes into account the potential differences inherent, not only in phenotypes and clinical evolution in IBD along the life, but also the changes in the environmental factors and the possible differences in the response of the host to them and to the use of different therapies.

The scientific committee has tried to put together a number of specialists able to explain the differences in the pathogenesis, clinical manifestations and evolution and therapeutic approaches in order to obtain the greatest benefits, the lower rate of unwanted effects and the better quality of life along the life of these patients.

We think that we all will learn from other specialists and will get a better understanding of this complex group of diseases, complex by themselves but also different in different age groups in order to treat these in the best personalized way.

I look forward to meet you in Madrid.

Miquel A. Gassull
Director
Health Science Research Institute
Germans Trias I Pujol Foundation
Badalona. Spain
IBD in Different Age Groups

Hotel Meliá Castilla, Madrid
Spain

Registration:
Thursday March 26, 2009
16.00 - 21.00 h
at the congress office

Information:
Prof. Dr. Miquel Gassull
Germans Trias I Pujol Foundation
Health Sciences Research Inst.
Carretera de Can Ruti
Cami de les Escoles, s/n
08916 Badalona
Spain
Telefon: +34 (0) 93/497 86 50
Telefax: +34 (0) 93/497 86 54
E-Mail: mgassull.germanstrias@gencat.net

Official Language:
English
(simultaneous translation into Spanish will be provided)

Poster Session:
For details see page 10

Scientific Organization:
M. Gassull, Badalona (Spain)
A. Levine, Holon (Israel)
A. López San Román, Madrid (Spain)
G. Rogler, Zurich (Switzerland)

Congress Venue:
Hotel Meliá Castilla
Capitán Haya, 43
28020 Madrid
Spain
Friday, March 27, 2009

8.15 Welcome
M. Gassull, Badalona

Session I
Insights from epidemiology
Chair: M. Gassull, Badalona; M. Sans, Barcelona

8.30 Epidemiology of IBD – Is there a shift towards younger ages?
C. P. Braegger, Zurich

8.55 Disease behaviour in adult patients – Are there predictors for stricture or fistula formation?
I. Dotan, Tel Aviv

9.20 Pediatric IBD – Is it different?
A. Levine, Tel Aviv

9.50 Environmental factors affecting IBD – Have we made progress?
P. Lakatos, Budapest

State-of-the-Art Lecture I
Chair: J.-P. Hugot, Paris; F. Ruemelle, Paris

10.15 Susceptibility genes and overall pathogenesis of IBD – Where do we stand?
C. Fiocchi, Cleveland

10.45 Coffee break with poster session

Session II
Pathophysiology of IBD and age of onset
Chair: C. Fiocchi, Cleveland; G. Rogler, Zurich

11.15 Genetic determinants of pediatric IBD – Is age of onset genetically determined?
S. Kugathasan, Atlanta

11.40 The epithelial barrier – Is it impaired in older ages?
A. Sturm, Berlin

12.05 The link between autophagy and innate immunity
V. Deretic, Albuquerque

12.30 The microbiota in IBD in different age groups
S. Cucchiara, Rome

12.55 Lunch break with poster session

20 minutes lecture, 5 minutes discussion
Friday, March 27, 2009

Session III
Differences in the diagnostic procedures
Chair: S. Danese, Rozzano; M. Zeitz, Berlin

14.00 What role do serological markers play in IBD – Pediatric and adult data
M. C. Dubinsky, Los Angeles

14.25 Controversies in use of diagnostic procedures
B. Vucelic, Zagreb

14.50 The risk of radiation and choice of imaging
H. Herfarth, Chapel Hill

15.15 Non invasive monitoring of mucosal healing in IBD.
The role of bowel ultrasound
F. Parente, Lecco

15.40 Coffee break with poster session

Session IV
Management of Crohn’s disease
Chair: A. Levine, Tel Aviv; G. Veereman-Wauters, Antwerp

State-of-the-Art Lecture II

16.10 Risk/benefit strategies have to be employed in the management of pediatric Crohn’s disease
J. Hyams, Hartford

16.40 Enteral nutrition as primary therapy in pediatric Crohn’s disease
R. Heuschkel, Cambridge

17.05 Top down therapy – Is the evidence strong enough?
E. Domènech, Badalona

17.30 Immunomodulation with methotrexate – Underused and undervalued?
F. M. Ruemmele, Paris

17.55 Partial enteral nutrition as a maintenance therapy?
P. Lionetti, Florence

18.20 End of afternoon session

20 minutes lecture, 5 minutes discussion
Saturday, March 28, 2009

Session V
Management of ulcerative colitis
Chair: A. López San Román, Madrid; F. Gomollón García, Zaragoza

8.30 Treatment of severe ulcerative colitis
S. Vavricka, Zurich

8.55 Treatment of severe pediatric ulcerative colitis
D. Turner, Jerusalem

9.20 Treatment of ulcerative colitis in the elderly
D. Binion, Milwaukee

9.45 Surgery in ulcerative colitis – Indication and timing
J. D. Söderholm, Linköping

10.10 Coffee break with poster session

Session VI
Tailored therapy for specific subgroups?
Chair: B. Feagan, London (ONT); V. Motilva, Sevilla

10.40 Management of IBD during pregnancy
A. Dignass, Frankfurt

10.55 Mild to moderate Crohn’s disease – Still room for step up therapies? – Adult perspectives
S. Bar-Meir, Tel Aviv

11.30 Anti TNF non responders – Therapeutic strategies
E. Louis, Liège

11.55 Early IBD: Different treatment response to specific or all medications?
J. Markowitz, New Hyde Park (NY)

State-of-the-Art Lecture III

12.20 After TNF: Next generation biologics
D. K. Podolsky, Dallas

12.50 Lunch break with poster session

20 minutes lecture, 5 minutes discussion
Saturday, March 28, 2009

14.00 Presentation of poster prizes
   G. Rogler, Zurich

Session VII
Specific management issues
Chair: G. Rogler, Zurich; B. Vucelic, Zagreb

14.10 How do we manage vaccinations in patients with IBD
   M. Esteve, Barcelona

14.35 Non colorectal malignancies in IBD – More than meets the eye
   L. Beaugerie, Paris

15.00 CRC prevention in patients with ulcerative colitis – Are pediatricians doing enough?
   M. D. Rutter, Stockton-on-Tees

15.25 Transition from pediatric to adult health care
   J. C. Escher, Rotterdam

15.50 Coffee break with poster session

Session VIII
Are we approaching solutions for unresolved problems?
Chair: E. Ricart, Barcelona; J. van der Woude, Rotterdam

16.20 Fistula treatment: The unresolved challenge
   P. Michetti, Lausanne

16.45 Drug monitoring in IBD: Helpful or dispensable?
   A. Stallmach, Jena

17.10 Growth retardation in early onset IBD: Should we monitor and treat these patients differently?
   A. M. Griffiths, Toronto

17.35 Prebiotics, probiotics and helminths: The “natural” solution?
   F. Guarner, Barcelona

18.00 End of meeting

20 minutes lecture, 5 minutes discussion
Poster Session

Posters will be exhibited on March 27-28, 2009 at the Hotel Meliá Castilla in Madrid. The authors will be in attendance during coffee and lunch breaks on both days.

1. The effect of infliximab treatment on angiogenic factors levels in patients with inflammatory bowel disease

2. Hepatitis B status and flare in Asian patients with inflammatory bowel disease receiving immunosuppression therapy
   V.J. Appleby, P. Southern, J. Healey, D. Patterson, S. Moreea (Bradford, GB)

3. The behavior of ulcerative colitis (UC) in elderly patients
   A. Atanassova, I.A. Kotzev, B. Manevska (Varna, BG)

4. Role of upper GI endoscopy in the initial diagnosis of children with IBD
   C. Banciu, I. Simedrea, L. Marian, I. Romosan (Timisoara, RO)

5. Adverse effects of pharmacologic treatment in children with inflammatory bowel disease

6. Glutathione peroxidase activity in ulcerative colitis
   G. Baskol, M. Baskol, F. Dogruel, A. Yurci, S. Gursoy, E. Torun (Kayseri, TR)

7. Adenosine deaminase and xanthine oxidase activities in ulcerative colitis
   M. Baskol, G. Baskol, A. Caniklioglu, F. Dogruel, A. Yurci, S. Gursoy, E. Torun (Kayseri, TR)

8. CARD15/NOD2 gene mutations and the onset Crohn's disease in Slovak patients
   M. Batovsky, L. Bartosova (Bratislava, SK; Brno, CZ)

9. What factors influence adhesion to therapy in inflammatory bowel disease?
10. Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease
F. Bermejo, A. López San Roman, A. Algaba, M. Van Domselaar, J.P. Gisbert, J.A. Carneros, E. Garrido, M.P. Valer, M. Rodríguez-Gandía, B. Piqueras (Fuenlabrada, Madrid, E)

11. Folate and B12 vitamin deficiency in Crohn’s disease: Prospective controlled analysis of their prevalence and risk factors

12. Infliximab versus parenteral methotrexate for maintenance and induction therapy in pediatric inflammatory bowel disease
B. Bidmon-Fliegenschnee, B. Raubal, J. Pichler, W.-D. Huber (Vienna, A)

13. Long-term budesonide treatment of collagenous colitis
O.K. Bonderup, J.B. Hansen, P.S. Teglbjaerg, J. Fallingborg (Randers, Aalborg, DK)

14. Idiopathic pancreatitis at or before inflammatory bowel disease is more frequent in pediatric patients
E. Broide, B. Weiss, I. Dotan, M. Wilschanski, B. Yerushalmi, A. Klar, A. Lerner, A. Levine (Zerifin, Tel Aviv, Jerusalem, Beer Sheva, Holon, IL)

15. Pregnancy and IBD patients
A. Chavoushian, H. Kadian, Z. Spassova, S. Stoinov, P. Penchev (Sofia, BG)

16. Biological agents in Greek children with inflammatory bowel disease

17. Comparative intestinal anti-inflammatory effects of different probiotics in the TNBS model of rat colitis
M. Comalada, B. Arribas, E. Bailón, D. Camuesco, A. Zarzuelo, L. Perán, M.E. Rodríguez-Cabezas, A. Nieto, A. Concha, J. Gálvez (Granada, E)

18. Oral tacrolimus in steroid-refractory pediatric ulcerative colitis
D. Comito, A. Famiani, V. Raffa, P. Rossi, R. Gallizzi, C. Romano (Messina, I)

19. Lymphoproliferative disorders diagnosed in an inflammatory bowel disease unit
M. Van Domselaar, A. López San Roman, E. Garrido (Madrid, E)

20. Colorectal cancer incidence during 10 years surveillance among IBD patients
V. Draganov, L. Tankova, P. Penchev, C. Velikova (Sofia, BG)
21. Oral beclomethasone dipropionate in pediatric active ulcerative colitis: A comparison trial with mesalazine
A. Famiani, C. Romano, D. Comito, P. Rossi, V. Raffa, W. Fries (Messina, I)

22. Interest use of pelvic magnetic resonance imaging in patients with Crohn's disease perineal fistulae
M. Fekih, S. Ouerdiane, K. Nouira, S. Matri, L. Kallel, J. Boubaker, A. Filali (Tunis, TN)

23. Epithelial barrier impairment in ulcerative colitis - Ultrastructural comparison between young and elderly
O. Fratila, T. Ilias, C. Craciun, G. Avram, R. Mihaila (Oradea, Cluj-Napoca, Sibiu, RO)

24. The immunomodulatory properties of Escherichia coli Nissle 1917 are not restricted to the gastrointestinal tract
J. Gálvez, M. Comalada, B. Arribas, M.E. Bailón, D. Camuesco, A. Zarzuelo, P. Utrilla, M.E. Rodríguez-Cabezas (Granada, E)

25. Infliximab in ulcerative colitis: Concomitant cytomegalovirus infection, life's quality, PPD positive have an influence on the treatment with infliximab?
S. Gómez Senent, L. Adán Merino, E. Martín Arranz, M.D. Martín Arranz, C. Froilán Torres, J.M. Segura Cabral (Madrid, E)

26. Ulcerative colitis associated with aphthous stomatitis

27. Immune deficiency in infants' malnutrition associated with inflammatory bowel disease
S.R. Gotia, M. Cucuruz, S.L. Gotia (Timisoara, RO)

28. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the etiology of ulcerative colitis - A European prospective cohort study
A.R. Hart (Norwich, GB)

29. Enteral nutrition vs. corticosteroids in pediatric patients with CD - Retrospective comparison study
I. Hojsak, Z. Misak, S. Abdovic, A. Jaklin-Kekez, O. Jadresin, S. Kolacek (Zagreb, HR)

30. Ulcerative colitis in elderly: Epidemiological, clinical, endoscopic and immunohistochemical study in a population from Western Romania
T. Ilias, O. Fratila, C. Craciun, G. Avram, R. Mihaila (Oradea, Cluj-Napoca, Sibiu, RO)

31. Incidence, phenotype and surgery in pediatric inflammatory bowel disease patients: Changes over a 44-year period
C. Jacobsen, A. Paerregaard, P. Munkholm, V. Wewer (Copenhagen, DK)
32. Impact of biliary and nutritional lack of phospholipids in a colitis mouse model
J. Jahnel, T. Claudel, A. Baghdasaryan, D. Silbert, J. Gumhold, A. Fuchsbiicher,
C. Langner, M. Trauner (Graz, A)

33. Anorectal lesions in Crohn's disease: Are there age-specific differences?
J. Jongen, A. Eberstein, J.-U. Bock, H.-G. Peleikis, V. Kahlke (Kiel, D)

34. Psychoemotional peculiarities in adolescents with inflammatory bowel diseases
L. Jorjoliani, E. Chkhartishvili, M. Tskhakaia, R. Karseladze, L. Saginadze (Tbilisi, GEO)

35. Prognostic value of intestinal bacterial flora and mucosal immunity during
infancy in the development of inflammatory bowel diseases in adults
L. Jorjoliani, R. Karseladze, L. Saginadze, T. Bigvava, T. Arakhamia,
E. Chkhartishvili (Tbilisi, GEO)

36. Particularities of Crohn's disease in young patients compared to adults
L. Kallel, N. Nija, S. Matri, M. Fekih, N. Ben Mustapha, S. Karoui, J. Boubaker,
A. Filali (Tunis, TN)

37. Fecal calprotectin remains stable in inactive Crohn's disease patients: Results of a
prospective study
Kaabachi, A. Filali (Tunis, TN)

38. Protease inhibitors genetic system phenotypes in inflammatory bowel disease
R. Karseladze, L. Jorjoliani, L. Saginadze, E. Karseladze (Tbilisi, GEO)

39. Diagnoses of ulcerative colitis in dependence on the age of patients
M. Konecny, V. Prochazka, J. Ehrmann (Olomouc, CZ)

40. Autophagy 16-like 1 (ATG16L1) is associated with inflammatory bowel disease
(IBD) in children
M. Lacher, S. Schröpf, A. Jurik, D. von Schweinitz, A. Ballauff, P. Lohse,
H. Baurecht, R. Kappler, S. Koletzko (Munich, Essen, D)

41. The role of aluminum in bacterial induced colitis in young IL-10-deficient mice
(Haifa, IL; Chapel Hill, New York, Raleigh, USA)

42. Implementation of a day care unit for inflammatory bowel disease: Patients' satisfaction
M.D. Martín Arranz, E. Martín Arranz, S. Gómez Senent, L. Adán Merino,
C. Froilán Torres, J.M. Segura Cabral (Madrid, E)
43. Risk factors associated with failing to enteral nutrition in pediatric Crohn’s disease
Z. Misak, I. Hojsak, S. Abdovic, A. Jaklin-Kekez, O. Jadresin, S. Kolacek (Zagreb, HR)

44. Clinical course of adult ulcerative colitis (UC): A Markov model analysis of the multinational population-based prospective cohort of the European Collaborative Study of Inflammatory Bowel disease (EC-IBD)
S. Odes, H. Vardi, M. Friger, B. Moum, T. Bernklev, D. Esser, H. Waters, M.E. Elkjaer, R.W. Stockbrügger, E. Tsianos, P. Munkholm, E. Langholz (Beer Sheva, IL; Oslo, N; Leiden, Maastricht, NL; Malvern, USA; Copenhagen, DK; Ioannina, GR)

45. Risk factors of the low bone mineral density in patients with inflammatory bowel disease
A. Pacurari, C. Banciu, C. Serban, L.M. Susan, I. Romosan (Timisoara, RO)

46. Symptoms of functional gastrointestinal disorders (FGID) in patients with inflammatory bowel disease (IBD)
A. Pacurari, C. Banciu, M. Floare, C. Serban, I. Romosan (Timisoara, RO)

47. Neonatal colitis: Be aware of rare causes other than IBD
A. Paerregaard, L.F. Hansen, U. Engel (Copenhagen, DK)

48. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease and extraintestinal manifestations but not with NOD2/CARD15 or TLR4 genotype in a Hungarian inflammatory bowel disease cohort
M. Papp, I. Altorjay, K. Palatka, J. Tumpek, L. Lakatos, A. Kovacs, T. Molnar, Z. Barta, W. Stocker, J. Papp, G. Veres, P.L. Lakatos, Hungarian IBD Study Group (Debrecen, Veszprem, Budapest, Szeged, H; Lübeck, D)

49. Mannan-binding lectin levels and deficiency in a large Hungarian cohort of inflammatory bowel disease patients
M. Papp, I. Altorjay, K. Palatka, G. Farkas, J. Harsfalvi, L. Lakatos, K. Farkas, T. Molnar, A. Kovacs, G. Veres, J. Papp, P.L. Lakatos, Hungarian IBD Study Group (Debrecen, Szeged, Veszprem, Budapest, H)

50. Myocarditis and ulcerative colitis: An infrequent association

51. Activated beta1-integrin in normal colonic mucosa and in ulcerative colitis: Immunohistochemical study
A. Portyanko, J.V. Gorgun (Minsk, WR)
52. Genitointestinal fistulas on Crohn's disease; Clinical characteristics and response to therapy
   G. De La Poza, F. Bermejo, A. López San Roman, M. Van Domselaar, A. Algaba, J. Die, J. Alvarez (Madrid, Fuenlabrada, E)

53. Significance of immunoserological markers in Crohn's disease (CD) according to the age at diagnosis
   C. Preda, S.N. Turchina, M. Manuc, M. Ciocarlan, R. Iacob, R. Vadan, M. Diculescu (Bukarest, Bukarest, RO)

54. Epidemiological characteristics of inflammatory bowel disease in Albania
   S. Prifti, B. Kraja, M. Sina, I. Akshia (Tirana, AL)

55. CD83 as a marker of mature dendritic cells increased in Crohn's disease
   A. Pryczynicz, K. Guzinska-Ustymowicz, J. Czyzewska, D. Cepowicz, A. Kemona (Bialystok, PL)

56. Renal amyloidosis complicating Crohn's disease: Report of three cases
   A. Quaz, L. Kallel, M. Fekih, S. Matri, J. Boubaker, A. Filali (Tunis, TN)

57. Are probiotics useful in the treatment of inflammatory bowel disease (IBD)
   L. Radu, A. Pacurari, B. Pacurari, I. Romosan (Timisoara, RO)

58. The effect of inflammatory bowel disease (IBD) during pregnancy on long-term health and illness in children of IBD patients - A multicenter Israeli study
   S. Reif, A. Alper, D. Rachmilewitz, I. Dotan (Tel Aviv, IL)

59. The activation of iron regulatory protein 1 dominates iron homeostasis in inflamed intestinal epithelium
   R. Reifen, O. Savion, A. Kammer, S. Moshe, Y. Bujanover, B. Weiss, E. Meyron-Holtz (Rehovot, Haifa, Tel Aviv; IL)

60. Characteristics of the patients with inflammatory bowel diseases in Romania
    E.C. Rezi, A. Fraticiu (Sibiu, RO)

61. Colonoscopy in elder versus younger patients - A retrospective study comparing the risk of developing IBD and colorectal cancer at two different age groups of patients from Sibiu, Romania
    E.C. Rezi, A. Fraticiu (Sibiu, RO)

62. Correlation between ileocolonoscopic and video capsule examination in ankylosing spondylitis
    M. Rimbas, M. Marinescu, S. Caraiola, M. Parvu, C. Baicus, S. Bucurica, C. Tanasescu, M.R. Voiosu (Bucharest, RO)
63. Profile of Belgian pediatric Crohn's disease subjects (2): Snap shot at diagnosis
M. Rogalidou, I. Hoffman, T. Mahler, S. Staelens, S. Van Biervliet, M. Scaillon, 
P. Bontems, I. Paquot, F. Bury, S. Colinet, W. Arts, B. Hauser, F. Smets, E. Sokal, 
P. Alliet, E. Janssens, O. Bauraind, I. Etienne, G. Veereman-Wauters (Antwerp, 
Leuven, Gent, Brussels, Liege, Genk, Hasselt, Ottignies, B)

64. Profile of Belgian pediatric Crohn's disease subjects (1): Demography and 
backround of the first 100 patients
M. Rogalidou, I. Hoffman, T. Mahler, S. Staelens, S. Van Biervliet, M. P. Bontems, 
I. Paquot, F. Bury, S. Colinet, W. Arts, B. Hauser, F. Smets, E. Sokal, P. E. Janssens, 
O. Bauraind, I. Etienne, G. Veereman-Wauters (Antwerp, Leuven, Gent, Brussels, 
Liege, Genk, Hasselt, Ottignies, B)

65. Methotrexate for pediatric IBD: Induction and maintenance of remission in a 
regional cohort study
P. Rogers, A. Tybulewicz, D. Hoole, J. Satsangi, P.M. Gillett, D.C. Wilson 
(Edinburgh, GB)

66. Early atherosclerosis in inflammatory bowel disease patients
C. Serban, L.M. Susan, A. Pacurari, C. Banciu, V.M. Ancusa, G. Savoiu, 
I. Romosan (Timisoara, RO)

67. A study of colorectal cancer in inflammatory bowel disease
C. Serban, M. Munteanu, L.M. Susan, C. Banciu, A. Pacurari, R. Dumache, 
G. Savoiu, I. Romosan (Timisoara, RO)

68. Arachidonic acid increases ulcerative colitis risk - A prospective cohort study in 
EPIC-Denmark using biomarker data
(Norwich, GB; Copenhagen, Aarhus, Aalborg, DK)

69. Mucosal healing and complete regression of transmural inflammation with 
doubling the third infliximab induction dose in refractory Crohn colitis 
M. Sladek, A. Swiat, I. Herman-Sucharska, S. Pieczarkowski, Z. Grzenda- 
Adamek, K. Fyderek (Cracow, PL)

70. A two-year longitudinal study of the anemia associated with inflammatory 
bowel disease
L.M. Susan, C. Serban, C. Banciu, A. Pacurari, V.M. Ancusa, S.R. Gotia, 
I. Romosan (Timisoara, RO)

71. Predictive value of serologic markers in inflammatory bowel disease 
L.M. Susan, C. Serban, C. Banciu, A. Pacurari, V.M. Ancusa, G. Savoiu, 
I. Romosan (Timisoara, RO)
72. Fertility and outcomes of pregnancies fathered by male patients exposed to thiopurines

73. Experience of infliximab therapy for refractory ulcerative colitis in a district general hospital
I. Tetlay, D. Sadigh, D. Hughes, R. Turner, J. O’Brien, G. Bray, M. McStay (High Wycombe, GB)

74. Ulcerative colitis in young patients - Epidemiological and clinical course in North-Eastern Romania county
E. Toader, L. Croitoru, O. Arhip, R. Mihaila (Iasi, Suceava, Botosani, Barlad, RO)

75. Perinuclear anti-neutrophil cytoplasmic antibodies in patients with inflammatory bowel disease and their first degree in North-Eastern Romania areas
E. Toader, C. Durnea (Iasi, RO)

76. Extraintestinal manifestations in pediatric patients with inflammatory bowel disease

77. Cytokine profile in autoimmune liver disease-inflammatory bowel diseases (overlap syndrome)
E.A. Torres, O.S. Shifrin, V.B. Zolotatevsky, V.T. Ivashkin (Moscow, R)

78. Endoscopic diagnosis versus histopathologic diagnosis in inflammatory bowel disease (IBD)
S.N. Turchina, C.M. Preda, G. Becheanu, M. Dumbrava, C. Gheorghe, M. Diculescu (Bucharest, RO)

79. A prospective multicenter study of outcomes and predictors of response in severe pediatric ulcerative colitis

80. Epidemiological risk factors for childhood onset inflammatory bowel disease in Scotland: A case-control study
81. Childhood-onset versus adult-onset inflammatory bowel disease: Phenotype
J. Van Limbergen, R.K. Russell, H.E. Drummond, M.C. Aldhous, N. Round,
E.R. Nimmo, P.M. Gillett, P. McGrogan, L.T. Weaver, W.M. Bisset, G. Mahdi,
I. Arnott, J. Satsangi, D.C. Wilson (Edinburgh, Glasgow, Aberdeen, GB)

82. Characteristics of new pediatric IBD patients enrolled in the Hungarian Pediatric
IBD Registry (HUPIR)
G. Veres, P.L. Lakatos, M. Papp, Hungarian Pediatric IBD Registry Group
(Budapest, Debrecen, H)

83. Response to medical treatment in patients with Crohn's disease: The role of
NOD2/CARD15 mutations, disease phenotype and age of diagnosis
B. Weiss, O. Lebowitz, H. Fider, I. Maza, A. Levine, R. Shaoul, S. Reif,
Y. Bujanover, A. Karban (Tel-Hashomer, Holon, Tel-Aviv, Haifa, IL)

84. Role of the antioxidative enzyme Prdx6 in inflammatory bowel disease (IBD)
J. Zeitz, I. Frey-Wagner, E. Kresin, M. Fried, G. Rogler (Zurich, CH)
List of Speakers, Moderators and Scientific Organizers

Prof. Dr. Simon Bar-Meir  
Chaim Sheba Medical Center  
Department of Gastroenterology  
2 Sheba Road  
52 621 Tel Hashomer  
Israel  
barmeirs@yahoo.com

Dr. Laurent Beaugerie  
Hôpital Saint Antoine  
Department of Gastroenterology  
184, Rue du Faubourg St.-Antoine  
75571 Paris  
France  
laurent.beaugerie@sat.aphp.fr

David G. Binion, M.D.  
Associate Professor of Medicine  
Division of Gastroenterology, Hepatology and Nutrition  
University of Pittsburgh  
School of Medicine  
200 Lothrop Street  
Pittsburgh, PA 15213  
USA  
binion@pitt.edu

Prof. Dr. C. P. Braegger  
Universität Zürich  
Kinderspital  
Gastroenterologie und Ernährung  
Steinwiesstr. 75  
8032 Zürich  
Switzerland  
christian.braegger@kispi.unizh.ch

Prof. Dr. Salvatore Cucchiara  
Università di Roma  
Policlinico Umberto I  
Gastroenterologia Pediatrica  
Viale Regina Elena, 324  
00161 Roma  
Italy  
salvatore.cucchiara@uniroma1.it

Dr. Silvio Danese  
Istituto Clinico Humanitas  
IRCCS in Gastroenterology  
Via Manzoni, 56  
20089 Rozzano  
Italy  
sdanese@hotmail.com

Vojo Deretic, Ph.D.  
University of New Mexico  
School of Medicine  
Molecular Genetics & Microbiology  
900 Camino de Salud, NE  
Albuquerque NM 87131  
USA  
vderetic@salud.unm.edu

Prof. Dr. Axel Dignass  
Innere Medizin I  
Markus-Krankenhaus  
Wilhelm-Epstein-Str. 2  
60431 Frankfurt  
Germany  
axel.dignass@fdk.info

Dr. Eugenio Domènech  
Hospital Universitari Germans Trias i Pujol  
Department of Gastroenterology  
Carretera del Canyet s/n  
08916 Badalona  
Spain  
edomenech.germantrias@gencat.cat

Dr. Iris Dotan  
Tel Aviv Medical Center  
Ichilov Hospital  
Department of Gastroenterology  
6, Weizman Street  
64239 Tel Aviv  
Israel  
irisd@tasmc.health.gov.il
Marla C. Dubinsky, M.D.
Assistant Professor of Pediatrics
Univ. of California, Los Angeles
Cedars-Sinai Medical Center
Pediatric IBD Center
8635 West Third Street
Los Angeles CA 90048
USA
dubinskym@csmc.edu

Dr. Johanna C. Escher
Erasmus Medical Center
Laboratory of Gastroenterology & Hepatology
Gravendijkwal 230
3015 CE Rotterdam
Netherlands
j.escher@erasmusmc.nl

Dr. Maria Esteve
Hospital Universitari
Mutua de Terrassa
Plaza Dr. Robert 5
08221 Terrassa/Barcelona
Spain
mestevecomas@telefonica.net

Dr. Brian G. Feagan
University of Western Ontario
Robarts Research Institute
LCTR G
100 Perth Drive
London ON N6A 5K8
Canada
bfeagan@robarts.ca

Claudio Fiocchi, M.D.
Professor of Medicine
The Cleveland Clinic Foundation
Pathobiology / NC 20
9500 Euclid Avenue
Cleveland OH 44195
USA
fiocchc@ccf.org

Prof. Dr. Miquel Gassull
Germans Trias i Pujol Foundation
Health Sciences Research Inst.
Carretera de Can Ruti
Cami de les Escoles, s/n
08916 Badalona
Spain
mgassull.germanstrias@gencat.net

Dr. Fernando Gomollón García
Hospital Clínico Universitario
Losano Blesa
Servicio de Gastroenterología
Avenida San Juan Bosco 15
50009 Zaragoza
Spain
fgomollon@gmail.com

Dr. Anne M. Griffiths
University of Toronto
The Hospital for Sick Children
Department of Gastroenterology
Room 1448
555 University Avenue
Toronto ON M5G 1X8
Canada
anne.griffiths@sickkids.ca

Dr. Francisco Guarner
Hospital General Vall d'Hebron
Servicio de Patología Digestiva
Paseo Vall d'Hebron 119
08035 Barcelona
Spain
fguarner@vhebron.net

Hans Herfarth, M.D.
Associate Professor of Medicine
University of North Carolina
Gastroenterology & Hepatology
4151 Bioinformatics Bldg.
130 Mason Farm Road
Chapel Hill NC 27599-7080
USA
hherf@med.unc.edu
Dr. Robert Heuschkel  
University of Cambridge  
Addenbrookes Hospital  
Pediatric Gastroenterology  
Hills Road  
Cambridge CB2 0QQ  
Great Britain  
robert.heuschkel@addenbrookes.nhs.uk

Dr. Jean-Pierre Hugot  
Hôpital Robert Debré  
INSERM U 843  
48, Bd. Sérurier  
75019 Paris  
France  
jean-pierre.hugot@rdb.ap-hop-paris.fr

Jeffrey S. Hyams, M.D.  
Professor of Pediatrics  
Connecticut Children’s Medical Center  
Department of Gastroenterology  
282 Washington Street  
Hartford CT 06106  
USA  
jhyams@ccmckids.org

Subra Kugathasan, M.D.  
Assoc. Professor of Pediatrics  
Emory University  
School of Medicine  
Department of Pediatrics  
201 Dowman Drive  
Atlanta GA 30322  
USA  
s.kugath@emory.edu

Prof. Dr. Peter Lakatos  
Semmelweis University  
Medical School  
I Department of Medicine  
Koranyi u. 2/a  
1083 Budapest  
Hungary  
kislakpet@bel1.sote.hu

Dr. Arie Levine  
E. Wolfson Medical Center  
Pediatric Gastroenterology & Nutrition  
P. O. Box 5  
58 100 Holon  
Israel  
avine@wolfson.health.gov

Dr. Paolo Lionetti  
Ospedale Pediatrico Meyer  
Department of Pediatrics  
Viale Pieraccini, 24  
50139 Firenze  
Italy  
lionetti@unifi.it

Dr. Antonio López San Román  
Hospital Universitario Ramon y Cajal  
Servicio de Gastroenterología  
Planta-1, izq.  
Carretera Colmenar KM 9,100  
28034 Madrid  
Spain  
alopezs@meditex.es

Dr. Edouard Louis  
C.H.U. Sart Tilman  
Gastro-enterologie  
4000 Liège  
Belgium  
edouard.louis@ulg.ac.be

James F. Markowitz, M.D.  
Schneider Children’s Hospital  
Pediatric Gastroenterology  
269-01 76th Avenue  
New Hyde Park NY 11040  
USA  
jmarkowi@nshs.edu

Prof. Dr. Pierre Michetti  
C.H.U.V.  
Département de Médecine Interne  
Division de la Gastroentérologie  
Rue du Bugnon 46  
1011 Lausanne  
Switzerland  
pierre.michetti@chuv.ch
Dr. Stephan Vavricka  
Universitätsspital Zürich  
Klinik für Gastroenterologie & Hepatologie  
Rämistrasse 100  
8091 Zürich  
Switzerland  
stephan.vavricka@usz.ch

Dr. Gigi Veereman-Wauters  
Pediatric Gastroenterology & Nutrition  
Queen Paola Children’s Hospital  
Lindendreef 1  
2020 Antwerp  
Belgium  
gveereman@skynet.be

Prof. Dr. Boris Vucelic  
University Hospital Rebro  
Division of Gastroenterology  
Department of Medicine  
Kispaticeva 12  
10000 Zagreb  
Croatia  
boris.vucelic@zg.htnet.hr

Dr. C. Janneke van der Woude  
Erasmus Medical Center  
Afd. Gastroenterologie  
Dr. Molewaterplein 40  
3015 GD Rotterdam  
Netherlands  
c.vanderwoude@erasmus.nl

Prof. Dr. Martin Zeitz  
Medizinische Klinik I  
Charité Universitätsmedizin  
Campus Benjamin Franklin (CBF)  
Hindenburgdamm 30  
12203 Berlin  
Germany  
martin.zeitz@charite.de
Congress Office

During the Falk Symposium 168

Hotel Meliá Castilla
Capitán Haya 43
28020 Madrid
Spain

Telephone: +34 91/567 83 21
Telefax: +34 91/567 83 23

Opening Hours:
Thursday, March 26, 2009 16.00-21.00 h
Friday, March 27, 2009 7.30-18.20 h
Saturday, March 28, 2009 8.00-18.00 h

Congress Fees

Scientific program of the Falk Symposium 168 € 200,-
Students and residents € 100,-

* * * OR* **

Day ticket € 120,-
For students and residents € 60,-

The congress fees include:
- Welcome Evening on March 26, 2009
- Refreshments during coffee breaks
- Lunch on March 27 and 28, 2009
- A copy of the symposium's abstract volume

Admission to Scientific Events

For admission to scientific events your name badge should be clearly visible.
Congress Report

The official congress report of the Falk Symposium 168 “IBD in Different Age Groups” will be published in English in the second half of 2009 by Karger publishers, Basel, Switzerland. Orders for this book at a reduced subscription price of € 35,- can be placed at the Congress Office during the congress in Madrid.

Congress Short Report

The congress short report of the Falk Symposium 168 “IBD in Different Age Groups” will be published by the Falk Foundation e.V. with the number FSK 168 in the second half of 2009.

Orders for this short report, free of charge, can be placed with the Falk Foundation e.V.

Airport

International Airport Madrid
Innovative Drugs
for bowel and liver diseases
Modern formulations and specially designed delivery systems ensure targeted release of the active drug

Scientific Dialogue
in the interest of therapeutic progress
More than 200 Falk Symposia and Workshops, attended by some 100,000 participants from over 100 countries since 1967
Over 13,000 continuing medical education seminars, attended by more than one million physicians and patients in Germany alone
Comprehensive literature service with more than 200 publications for healthcare professionals as well as patients and their families

www.falkfoundation.com  www.drfalkpharma.com
Leinenweberstr. 5  79108 Freiburg  Germany  Tel +49 (0)761/1514-0  Fax +49 (0)761/1514-321  Mail zentrale@drfalkpharma.de